Clinical Results Announcement

D&D Pharmatech disclosed data linking its proprietary GLP‑1·glucagon receptor agonist to improvements in liver fibrosis and MASH (metabolic dysfunction-associated steatohepatitis). While GLP‑1 has traditionally been used for weight loss and glycemic control, this study suggests it may also exert beneficial effects on hepatic metabolism. The agonist simultaneously activates the receptors for both GLP‑1 and glucagon, aiming for integrated metabolic regulation.

Need for Liver Fibrosis and MASH Therapies

Liver fibrosis is a progressive condition that often progresses to cirrhosis, and MASH currently lacks any approved therapies. The mechanism whereby GLP‑1 agonists reduce inflammation and inhibit lipid accumulation, thereby mitigating tissue injury, is gaining attention. This mechanism is regarded as a novel approach distinct from existing treatments.

Competitive Landscape and Differentiation

Globally, Novo Nordisk’s Wegovy dominates the GLP‑1‑based obesity market, yet the liver‑disease indication remains untapped. If D&D’s candidate succeeds, it could expand the GLP‑1 pipeline and generate a new revenue stream. This would provide a strategically significant, differentiated clinical portfolio relative to existing competitors.

Investment and Partnership Attraction Potential

These results showcase the research capabilities of a Korean biotech on the international stage, likely drawing interest from investors and large pharmaceutical companies. Should the program advance beyond Phase 2, partnership negotiations or licensing agreements could accelerate. However, regulatory approval will require additional clinical data and long‑term safety validation.

Potential Impact on Patients

Hundreds of millions of individuals worldwide are affected by MASH, yet effective therapies are lacking. If D&D’s candidate achieves clinical success, it could become the first disease‑modifying agent, substantially improving patient quality of life and delivering a new therapeutic option to clinical practice.